LATS1 and ovarian serous adenocarcinoma: Recently, a study evaluated immunohistochemistry data from Chinese ovarian cancer samples and showed that LATS1 and LATS2 expression was reduced in serous ovarian cancer patients associated with shorter survival and increased recurrence, while LATS1 and LATS2 were highly expressed in fallopian tube and LATS1 was expressed in normal ovarian tissue (Xu et al. 2015).